Disease Burden and Management of Vitiligo

A panel of experts open a discussion surrounding vitiligo, including the definition and nature of the disease.

David Rosmarin, MD, discusses the prevalence and incidence of vitiligo across a diverse patient population.

Vitiligo’s effects on clinical burden and patient quality of life are addressed by Brett King, MD, PhD, and David Rosmarin, MD.

David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo.

Comorbidities and disease states associated with vitiligo are explored by a panel of key opinion leaders.

Dr Dunn leads a discussion outlining frontline therapies for the treatment of vitiligo.

The panel of experts address the economic burden of vitiligo from payer and provider perspectives.

Key opinion leaders discuss how diagnosing vitiligo can lead to myriad treatment options.

A variety of treatment options for vitiligo are explored by Drs Dunn, Rosmarin, and King.

Navigating payer and provider considerations to ensure optimal care management for vitiligo.

The panel navigates unmet needs surrounding the vitiligo treatment landscape.

Dr Rosmarin illustrates treatment management of vitiligo with the use of JAK inhibitors.

Safety considerations, particularly surrounding JAK inhibitors in vitiligo treatment, are emphasized by the panelists.

Dr King presents interleukin-15, a non-JAK inhibitor therapy option for the treatment of vitiligo.

The panel discusses emerging treatments for vitiligo and addresses opportunities for payers to support implementation.

Experts provide closing pearls regarding the current and prospective treatment landscape of vitiligo.